The collaboration will utilize KineMed’s Dynamic Proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
KineMed R&D executive vice-president Scott Turner said they are collaborating with Pfizer in taking novel and innovative approaches, by targeting disease pathways that have previously remained undeveloped as drug targets.
"We are using our translational platform to accelerate and rapidly de-risk the advancement of novel compounds in pre-clinical and clinical trials," Turner added.